Innovate UK, GB: Innovative technologies: Nucleic acid medicines manufacture

01/06/2023

19/07/2023

The aim of this competition is to improve the resource efficiency, productivity and scalability for the manufacture of nucleic acid medicines in the UK. Our objective is to stimulate the development and implementation of innovative technologies to improve the resource efficiency, productivity and ability to manufacture nucleic acid medicine. This must allow for growth at scale including, but not limited to, emerging products targeting large patient populations. Your project must be focused on the manufacturing of the active nucleic acid medicines, either the ingredients or formulated products. You must be able to demonstrate an improvement in resource efficiency, productivity or throughput as compared with current manufacturing technology, utilising a recognised metric, for example, with process mass intensity.

The nucleic acid medicines in scope for this competition include but are not limited to: small activating ribonucleic acid (RNA) messenger ribonucleic acid (mRNA), including self-amplifying mRNA antisense RNA or oligonucleotides small interfering, short interfering or silencing RNA short hairpin RNA micro RNA DNA

Applicant type Commercial or Private Sector; Government or Public Sector; Individuals: Early Career and Emerging in Field; Individuals: Mid-Career to Established in Field; Non-profit Eligibility Note Lead organisation To lead a project your organisation must: be a UK registered business of any size, research organisation, research and technology organisation (RTO), charity, not for profit or public sector organisation collaborate with other UK registered organisations be or work with at least one grant claiming micro, small or medium-sized enterprise (SME).